<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440385</url>
  </required_header>
  <id_info>
    <org_study_id>RPC01-3202</org_study_id>
    <secondary_id>U1111-1203-7949</secondary_id>
    <secondary_id>2017-004293-33</secondary_id>
    <nct_id>NCT03440385</nct_id>
  </id_info>
  <brief_title>Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease</brief_title>
  <official_title>Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect
      of oral ozanimod as an induction treatment for subjects with moderately to severely active
      Crohn's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a CDAI score &lt; 150 at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with average daily abdominal pain score ≤ 1 point, average daily stool frequency score ≤ 3, and stool frequency no worse than baseline at week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>Abdominal pain scores and stool frequency scores are patient reported outcomes collected from the patient diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a Simple Endoscopic Score for Crohn's Disease (SES-CD) decrease from baseline of ≥ 50% at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The SES-CD assesses the degree of endoscopic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score &lt; 150 at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CDAI reduction from baseline of ≥ 100 points with SES-CD decrease from baseline of ≥ 50% at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD and the SES-CD assesses the degree of endoscopic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CDAI score &lt; 150 with SES-CD decrease from baseline of ≥ 50% at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD and the SES-CD assesses the degree of endoscopic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CDAI score &lt;150 at Week 12 and SES-CD decrease from baseline of ≥ 50% at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD and the SES-CD assesses the degree of endoscopic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with histological improvement (ie. as measured by Global Histologic Disease Activity score changes (Geboes, 2000) at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>Global Histologic Disease Activity score is a measure of histologic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CDAI reduction from baseline of ≥ 70 points at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any ulcerated surface ≥10% at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>Ulcer size will be measured during endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of ≥ 50% at Week 12</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The CDEIS assesses the degree of endoscopic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) scores</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The IBDQ is a frequently used outcome parameter in clinical trials. The IBDQ is a responsive instrument for reflection quick change in the quality of life of patients with CD, within a 2-week period. The IBDQ has evolved into a standard for measuring disease-specific quality of life in patients with CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in 36-Item Short Form-36 Survey (SF-36) scores</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The medical outcomes SF-36 questionnaire provides a measure of the subject's health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Work Productivity and Activity Impairment Questionnaire (WPAI)-CD scores</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The WPAI-CD is a validated, reliable and responsive instrument that assesses the impact of CD on work and activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in EuroQol 5 dimensions questionnaire (EQ-5D) scores</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>The EQ-5D is a validated, 6-item, self-administered instrument designed to measure generic health status. It is applicable to a wide range of health conditions and treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in CD-related hospitalizations and surgery</measure>
    <time_frame>Up to approximately week 12</time_frame>
    <description>Healthcare Resource Utilization (HRU) will be evaluated in this study to assess the impact of CD on healthcare utilization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Administration of oral Ozanimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo capsule orally starting with a 7-day dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>Ozanimod</description>
    <arm_group_label>Administration of oral Ozanimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Administration of Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          1. Aged 18-75 years

          2. Crohn's disease for ≥ 3 months on endoscopy and on histological exam

          3. Inadequate response or loss of response to corticosteroids, immunomodulators, and/or
             biologic therapy

          4. Patient has met each of the following 2 criteria: 1) Crohn's Disease Activity Index
             (CDAI) score ≥ 220 and ≤ 450. 2) Average daily stool frequency ≥ 4 points and/or an
             abdominal pain of ≥ 2 points.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment or at the time
        point specified in the following criteria:

          1. Diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic
             colitis or known strictures or stenosis leading to symptoms of obstruction.

          2. Current stoma, ileal-anal pouch anastomosis, symptomatic fistula, or need for
             ileostomy or colostomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Crohn Disease</keyword>
  <keyword>Oral</keyword>
  <keyword>Ozanimod</keyword>
  <keyword>Moderately active</keyword>
  <keyword>Severely active</keyword>
  <keyword>RPC01</keyword>
  <keyword>RPC01-3202</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

